Research and development of new products is one of the priorities of JSC Grindeks – every year Grindeks reviews different versions of new medications in cooperation with the leading Latvian and international research organizations.

Referring to a publication in the information portal BNS on 15 February 2010, Grindeks affirms the information about the discussions with the Latvian Institute of Organic Synthesis on development of the new molecule of MildronateĀ®. However, no decisions have been made.

About JSC Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. The main directions of its operation are research, development, manufacturing and sales of original products, as well as generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, psychotropic and anti-cancer therapeutic groups of medications.

Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia; as well as representatives and representative offices in 14 countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and other CIS countries, as well as Japan and USA. The shares of JSC Grindeks are listed in the Official List of “Nasdaq OMX Riga”.


Ilze Kreicmane
JSC Grindeks PR specialist
Phones: (+371) 67083336, (+371) 26466681
Fax: (+371) 67083505